Aridis' mon­o­clon­al an­ti­body fails PhI­II, but plans for sec­ond tri­al any­way

Aridis Phar­ma­ceu­ti­cals’ mon­o­clon­al an­ti­body missed the bar in a Phase III test in ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia caused by the gram-pos­i­tive bac­te­ria S. au­reus, the com­pa­ny an­nounced Wednes­day. 

But Aridis is plan­ning for a sec­ond Phase III study any­way once it dis­cuss­es the find­ings with the FDA and the Eu­ro­pean Med­i­cines Agency. Ex­ecs blamed re­cruit­ment chal­lenges stem­ming from Covid-19 and Rus­sia’s in­va­sion of Ukraine for the miss, cut­ting their en­roll­ment tar­get in half.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER